Search

Your search keyword '"Blin N"' showing total 725 results
Start Over Author "Blin N"
725 results on '"Blin N"'

3. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas

Author

Tessoulin, B., Thomare, P., Delande, E., Moynard, J., Gastinne, T., Moreau, A., Bossard, C., Mahé, B., Blin, N., Dubruille, V., Touzeau, C., Boudreault, J. S., Perrin, F., Lok, A., Guillaume, T., Garnier, A., Peterlin, P., Gallas, P., Chevallier, P., Moreau, P., and Le Gouill, Steven

Published
2017
Full Text
View/download PDF

4. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience

Author

Bourcier, J., Gastinne, T., Leux, C., Moreau, A., Bossard, C., Mahé, B., Blin, N., Dubruille, V., Touzeau, C., Voldoire, M., Guillaume, T., Peterlin, P., Gallas, P., Garnier, A., Maisonneuve, H., Moreau, P., Juge-Morineau, N., Jardel, H., Chevallier, P., Moreau, P., and Le Gouill, S.

Published
2016
Full Text
View/download PDF

6. P56 - Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation: COMPARABLE OUTCOMES AMONG ADULT PATIENTS ALLOTRANSPLANTED FOR MYELODYSPLASTIC SYNDROME USING HAPLOIDENTICAL, MATCHED UNRELATED OR MATCHED SIBLING DONORS: A SINGLE-CENTER STUDY.

Author

Garnier, A., Jullien, M., Guillaume, T., Peterlin, P., Le Bourgeois, A., Mahe, B., Dubruille, V., Blin, N., Touzeau, C., Gastinne, T., Lok, A., Vantyghem, S., Moreau, P., Bene, M.C., Le Gouill, S., and Chevallier, P.

Published
2021
Full Text
View/download PDF

8. Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation

Author

Garnier, A., primary, Jullien, M., additional, Guillaume, T., additional, Peterlin, P., additional, Le Bourgeois, A., additional, Mahe, B., additional, Dubruille, V., additional, Blin, N., additional, Touzeau, C., additional, Gastinne, T., additional, Lok, A., additional, Vantyghem, S., additional, Moreau, P., additional, Bene, M.C., additional, Le Gouill, S., additional, and Chevallier, P., additional

Published
2021
Full Text
View/download PDF

23. Gut Microbiome Alteration in HIV/AIDS and the Role of Antiretroviral Therapy—A Scoping Review

Author

Zsófia Gáspár, Blin Nagavci, Bálint Gergely Szabó, and Botond Lakatos

Subjects
AIDS, acquired immunodeficiency syndrome, HIV, human immunodeficiency virus, microbiome, dysbiosis, Biology (General), QH301-705.5
Abstract

(1) Background: The gut microbiota plays a crucial role in chronic immune activation associated with human immunodeficiency virus (HIV) infection, acquired immune deficiency syndrome (AIDS) pathogenesis, non-AIDS-related comorbidities, and mortality among people living with HIV (PLWH). The effects of antiretroviral therapy on the microbiome remain underexplored. This study aims to map the evidence of the impact of integrase strand transfer inhibitors (INSTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) on the gut microbiota of PLWH. (2) Methods: A scoping review was conducted using PubMed, Web of Science, and Embase, with reports collected following PRISMA for Scoping Reviews (PRISMA-ScR). (3) Results: Evidence suggests that INSTI-based regimes generally promote the restoration of alpha diversity, bringing it closer to that of seronegative controls, while beta diversity remains largely unchanged. INSTI-based therapies are suggested to be associated with improvements in microbiota composition and a tendency toward reduced inflammatory markers. In contrast, NNRTI-based treatments demonstrate limited recovery of alpha diversity and are linked to an increase in proinflammatory bacteria. (4) Conclusions: Based on the review of the current literature, it is indicated that INSTI-based antiretroviral therapy (ART) therapy facilitates better recovery of the gut microbiome.

Published
2024
Full Text
View/download PDF

31. Tumour necrosis factor α and nuclear factor κB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide

Author

Loncar, MB, Al-azzeh, E-d, Sommer, PSM, Marinovic, M, Schmehl, K, Kruschewski, M, Blin, N, Stohwasser, R, Gott, P, and Kayademir, T

Subjects
Gene expression -- Physiological aspects -- Research -- Genetic aspects -- Health aspects, Colorectal diseases -- Research -- Causes of -- Health aspects -- Care and treatment -- Genetic aspects, Inflammatory bowel diseases -- Health aspects -- Causes of -- Genetic aspects -- Care and treatment -- Research, Tumor necrosis factor -- Genetic aspects -- Physiological aspects -- Health aspects -- Research, Gastrointestinal diseases -- Research -- Causes of -- Health aspects -- Care and treatment -- Genetic aspects, Health, Care and treatment, Physiological aspects, Research, Genetic aspects, Causes of, Health aspects
Abstract

Background and aims: Tumour necrosis factor α (TNF-α) induction of nuclear factor κB (NFκB) activation plays a major role in the pathogenesis of inflammatory bowel disease (IBD). Trefoil factor family [...]

Published
2003

34. Gastroprotective peptide trefoil factor family 2 gene is activated by upstream stimulating factor but not by c-Myc in gastrointestinal cancer cells. (Gastrointestinal Cancer)

Author

Al-azzeh, E., Dittrich, O., Vervoorts, J., Blin, N., Gott, P., and Luscher, B.

Subjects
Colon cancer -- Genetic aspects -- Development and progression, Adenocarcinoma -- Development and progression -- Genetic aspects, Stomach cancer -- Genetic aspects -- Development and progression, Health
Abstract

Background: Damage to the gastrointestinal mucosa results in the acute up-regulation of the trefoil factor family peptides TFF1, TFF2, and TFF3. They possess protective, healing, and tumour suppressive functions. Little [...]

Published
2002

35. Abstracts

Author

Kaatsch, Hans-Jürgen, Püschel, K., Heinemann, A., Klaas, Jakob, Graß, Hildegard, Staak, Michael, Benthaus, S., Vock, R., Brinkmann, B., Temme, O., Daldrup, T., Dilger, M., Fink, T., Rittner, Ch., Thali, Michael J., Braun, M., Brueschweiler, W., Kneubuehl, B. P., Vock, P., Wirth, J., Dirnhofer, R., Bohnert, M., Berger, H., Buck, U., Pollak, S., Gotta, J. C., Erdmann, F., Riße, M., Schütz, H., Weiler, G., Pragst, F., Auwärter, V., Sporkcrt, F., Roewer, L., Willuweit, S., Kayser, M., Nagy, M., de Knijff, P., Geserick, G., Augustin, C., Betz, A., Carracedo, A., Corach, D., Dupuy, B. M., Gusmaõ, L., Henke, L., Hidding, M., Kärgel, H. J., Lessig, R., Liebeherr, E., Parson, W., Pascali, V. L., Rolf, B., Schneider, P. M., Dobosz, T., Teifel-Greding, J., Krawczak, M., Bauer, M., Patzelt, D., Kuznik, J., Bondy, B., Eisenmenger, W., Möller, H. -J., Zehner, R., Niess, C., Amendt, J., Krettek, R., Weinmann, W., Görner, M., Goerke, R., Mahler, H., Fowinkel, C., Haarhoff, K., Schmidt, P., Schmolke, C., Mußhoff, F., Menzen, M., Prohaska, C., Madea, B., Kauert, G., Gleicher, S., Drasch, G., von Meyer, L., Roider, G., Quitterer, D., Kröner, L., Toennes, S. W., Jurowich, S., Käferstein, H., Sticht, G., Gilg, T., Priemer, F., Jocham, N., Fechner, G., Ortmann, Ch., Schulte, T., Nieschalk, M., Weirich, V., Rummel, J., Rentsch, D., Wegener, R., Berehaus, G., Graß, H., Grellner, W., Rettig-Stürmer, A., Kühn-Becker, H., Georg, T., Möller, M., Wilske, J., Kemmerling, R., Sachs, H., Menting, T., Musshoff, F., Schoenemeier, S., Bürrig, K. -F., Jacob, B., Bonte, W., Maeda, H., Zhu, B. -L., Fujita, M. Q., Quan, L., Ishida, K., Taniguchi, M., Böhme, B., Rauch, E., Penning, R., Amberg, R., Blackwell, C. C., Pelz, K., Meier, V., Saternus, K. -S., Gessler, F., Böhnel, H., Bouska, I., Toupalík, P., Klir, P., Kleemann, W. J., Ast, F., Beck, U., Debertin, S., Giebe, B., Heide, S., Sperhake, J., Poets, C. F., Weis, C., Schlaud, M., Bajanowski, T., Wedekind, H., Breithardt, G., Debertin, A. S., Tönjes, H., Tschernig, T., Pabst, R., Tröger, H. D., Krill, A., Hame, M., Bouška, I., Ježková, J., Kernbach-Wighton, G., Wense, A. v. d., Kijewski, H., Goeke, M., Weber, B., Staak, M., Dettmeyer, R., Driever, F., Becker, A., Wiestler, O. D., Verhoff, M. A., Woenckhaus, J., Hauri-Bionda, R., Strehler, M., Bär, W., Ohshima, T., Takayasu, T., Kondo, T., Sato, Y., Tarbah, Fuad A., Mahler, Hellmut, Temme, Oliver, Daldrup, Thomas, Pötsch, Lucia, Emmerich, Patricia, Skopp, Gisela, Andresen, H., Schmoldt, A., Thurau, K., Vogt, S., Große-Perdekamp, M., Pufal, E., Sykutera, M., Rochholz, G., Lis, G., Sliwka, K., Zörntlein, S., Röhrich, J., Pötsch, L., Becker, J., Mattern, Rainer, Yamamoto, Yoshiko, Hayase, Tamaki, Yamamoto, Keiichi, Piette, Michel H. A., De Letter, Els A., Cordonnier, Jan, Schultes, A., Pluisch, F., Darok, M., Kollroser, M., Mannweiler, S., Babel, B., Magerl, H., Mahfoud, B., Stein, S., Iwersen-Bergmann, S., Risser, D., Hönigschnabl, S., Stichenwirth, M., Sebald, D., Kaff, A., Schneider, B., Vycudilik, W., Bauer, G., Reitz, E., Kimont, H. -G., Molnár, A., Jeszenszky, E., Benkó, A., Száz, E., Varga, T., Mayr, N. P., Schmidbauer, S., Hallfeldt, K., Bank, A., Iffland, R., Schuff, A., Fischer, T., Weingarten, Y., Alt, A., Janda, I., Wurst, F. M., Seidl, S., Seitler, C., Haag-Dawoud, Munira, Beike, J., Vennemann, B., Köhler, H., Hendreich, F. -I., Giebe, W., Reimann, I., Werner, R., Klein, A., Schulz, K., Feischer, D., Erfurt, Ch., Arnold, R., Winnefeld, K., Riepert, T., Iffland, R., Longauer, F., Kardošovå, V., Anders, S., Hildebrand, E., Schulz, F., Möbus, U., Jaroß, W., Wittig, H., Schmidt, U., Hauptmann, K., Krause, D., Prudlow, B., Rohner, T., Molz, G., Früchtnicht, W., Hoppe, B., Henßge, C., Althaus, L., Herbst, J., Preiß, U., Stein, C., Glenewinkel, F., Leinzinger, E. P., Lászik, A., Soós, M., Hubay, M., Sótonyi, P., Schliff, A., Gatternig, R., Hering, S., Edelmann, J., Plate, I., Michael, M., Kuhlisch, E., Szibor, R., von Wurmb, N., Hammer, U., Meissner, D., Kirches, E., Dietzmann, K., Pfeiffer, H., Ortmann, C., Meißner, C., Mohamed, S. A., Warnk, H., Gehlsen-Lorenzen, A., Oehmichen, M., Heidorn, F., Henkel, R., Schulz, M. M., Reichert, W., Mattern, R., Baasner, A., Banaschak, S., Schäfer, C., Benecke, M., Reibe, S., Barksdale, Larry, Sundermeier, Jon, Ratcliffe, Brett C., Lutz, S., Hohoff, C., Schürenkamp, M., Kahle, C., Fieguth, A., Ritz-Timme, S., Laumeier, I., Schütz, H. W., Schulte-Mönting, J., Chaudri, S., Welti, M., Dittmann, V., Olze, A., Schmeling, A., Reisinger, W., Klotzbach, H., Gabriel, P., Demir, T., Huckenbeck, W., Reuhl, J., Schuster, R., Maxeiner, H., Bockholdt, B., Jachau, K., Kuchheuser, W., Försterling, T., Ehrlich, E., Besselmann, M., Du Chesne, A., Albrecht, U. -V., Guan, D. W., Dreßler, J., Voigtmann, K., Müller, E., Vieler, S., Kirchner, A., Humpert, M., Breitmeier, D., Mansouri, F., Wyler, D., Marty, W., Sigrist, Th., Zollinger, U., Meyer, U., Allmen, G. v., Karger, B., Hoekstra, A., Stehmann, B., Schmidt, P. F., Peschel, O., Vollmar, C., Szeimies, U., Rothschild, M. A., Kegel, D., Klatt, A., Klatt, C., Briese, B. -H., Schyma, C., Schyma, P., Angetter, Daniela, Perdekamp, M. Große, Sun, Y., Guttenberge, R., Riede, U. -N., Poetsch, M., Seefeldt, S., Maschke, M., Lignitz, E., Zeller, M., Wehner, H. -D., Czarnetzki, A., Blin, N., Bender, K., Emmerich, P., Pádár, Zs., Egyed, B., Kemény, G., Woller, J., Füredi, S., Balogh, I., Cremer, U., Scheil, H. -G., Schiwy-Bochat, K. -H., Althoff, H., Immel, U. -D., Tatschner, Th., Lang, C., Versmold, D., Reineke, Th., Mall, G., Dahlmann, F., Büttner, A., Hubig, M., Rötzscher, K., Grundmann, C., Oritani, S., Peter, J., Popov, V., Olejnik, V., Khokhlov, V. D., Stiller, D., Romanowski, U., Kleiber, M., Klupp, N., Mortinger, H., Chadová, L., Bouška, I., Toupalik, P., Schnabel, A., Lutz, F. -U., Crivellaro, A., Strauch, H., Dan, Dermengiu, Silvia, Dermengiu, Buda, Octavian, Kandolf, R., Kaiser, R., Eis-Hübinger, A. M., Kobek, M., Jankowski, Z., Rygol, K., Kulikowska, J., Martin, H., Kolbow, K., Keil, W., Wang, Huijun, Ding, Yanqing, Huang, Guangzhao, Wu, Zhongbi, Wehner, F., Subke, J., Zdravkovic, M., Otasevic, V., Rostov, M., Karadzic, R., Kildüschov, E. M., Buromski, I. W., Plaksin, W. O., Wendland, A., Spiridonow, W. A., Sabusow, J. G., Kalinin, J. P., Heide, S., Schmidt, V., Wiegand, P., Kleiber, M., Demmler, G., Zack, F., Reischle, S., Schönpflug, M., Beier, G., Berchtenbreiter, C., Lackner, K., Jendrusch, B., Wolf, H., Buhmann, D., Summa, H., Matschke, J., Stürenburg, H. J., Junge, M., Wischhusen, F., Müldner, C., Schröder, A., Kaiser, E., Lasczkowski, G., Hofbauer, V., Eberl, N., Thomson, H., Tatschner, T., Milz, S., Gazov, E., Trübner, K., Brenner, M., Tsokos, M., Anders, S., Paulsen, F., Reith, K., Bratzke, H., Schapfeld, R., Graefe-Kirci, U., Stiller, D., Trübner, K., and Schäfer, A. Th.

Published
2000
Full Text
View/download PDF

46. Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors

Author

Doz, F., Locatelli, Franco, Baruchel, A., Blin, N., De Moerloose, B., Frappaz, D., Dworzak, M., Fischer, M., Stary, J., Fuertig, R., Riemann, K., Taube, T., Reinhardt, D., Locatelli F. (ORCID:0000-0002-7976-3654), Doz, F., Locatelli, Franco, Baruchel, A., Blin, N., De Moerloose, B., Frappaz, D., Dworzak, M., Fischer, M., Stary, J., Fuertig, R., Riemann, K., Taube, T., Reinhardt, D., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Background: Volasertib induces mitotic arrest and apoptosis by targeting Polo-like kinases. In this phase I dose-escalation study, the maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary efficacy of volasertib were determined in pediatric patients. Methods: Patients aged 2 to <18 years with relapsed/refractory acute leukemia/advanced solid tumors (ST) without available effective treatments were enrolled—cohort C1 (aged 2 to <12 years); cohort C2 (aged 12 to <18 years). The patients received volasertib intravenously (starting dose: 200 mg/m2 body surface area on day 1, every 14 days). The primary endpoint was the pediatric MTD for further development. Results: Twenty-two patients received treatment (C1: leukemia, n = 4; ST, n = 8; C2: leukemia, n = 3; ST, n = 7). No dose-limiting toxicities (DLTs) occurred up to 300 mg/m2 volasertib in C1; two patients in C2, at 250 mg/m2 volasertib, had DLTs in cycle 1, one of which led to death; therefore, the MTD of volasertib in C2 was 200 mg/m2. The most common grade 3/4 adverse events (all patients) were febrile neutropenia, thrombocytopenia, and neutropenia (41% each). Stable disease (SD) was the best objective response (leukemia, n = 5; ST, n = 2); the duration of SD was short in all patients, except in one with an ST. PK profiles were generally comparable across dose groups and were consistent with those in adults. Conclusion: The pediatric MTD/dose for further development was identified. There were no unexpected safety or PK findings; limited antitumor/antileukemic activity was demonstrated.

Published
2019

49. The human beta(sub 3)-adrenoceptor: the search for a physiological function

Author

Emorine, L., Strosberg, A.D., and Blin, N.

Subjects
Beta adrenoceptors -- Physiological aspects, Fat metabolism -- Physiological aspects, Adipose tissues -- Physiological aspects, Biological sciences, Chemistry, Pharmaceuticals and cosmetics industries
Abstract

The presence of the mRNA of beta adrenoceptors in the adipose tissues and in the gall bladder and colon confirmed that beta adrenoceptors play a role in human physiological processes. Studies also showed that beta adrenoceptors are more abundant in internal adipose tissues than in the subcutaneous tissues. However, lipolysis revealed that its function decreases with age. Scientists are searching for procedures to increase its expression in adults and children to determine if it can be used in regulating obesity and intestinal processes,

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results